Compare ACADIA Pharmaceuticals Inc. (ACAD) vs AT&T Inc. (T) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs AT&T Inc. — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.85 (market cap $4.49B), while AT&T Inc. trades at $21.26 (market cap $146.54B). The key difference: AT&T Inc. is far larger — about 32.6× ACADIA Pharmaceuticals Inc.'s market cap, and AT&T Inc. pays a 5.26% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | T | |
|---|---|---|
Market Cap | $4.49B | $146.54B |
Sector | Health | Media |
52-Week High | $28.06 | $29.62 |
52-Week Low | $20.06 | $20.49 |
Enterprise Value | $3.69B | $291.89B |
Dividend Yield | — | 5.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
AT&T (T) trades at $21.06, up 2.38% today but remains near multi-year lows amid competitive pressures. The stock shows bearish technical signals with key support at $20, while fundamentals reveal strong profitability with a 16.94% net margin and attractive valuation at a P/E of 6.93. Recent earnings beats and a 5.4% dividend yield provide support, but SpaceX competition concerns dominate sentiment.
Outlook: Undervalued with significant upside to the $29.50 consensus target, but high debt and Starlink disruption risks temper near-term optimism. Investment case hinges on execution in fiber/wireless growth against stiff competition, with cash flow stability supporting the dividend.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About AT&T Inc.
AT&T Inc. is a communications holding company. The Company, through its subsidiaries and affiliates, provides local and long-distance phone service, wireless and data communications, Internet access and messaging, IP-based and satellite television, security services, telecommunications equipment, and directory advertising and publishing.
Read more on T →
